Hot news
- Leadman | The first team develo
- 2016 | The First Staff Birthday
- Leadman Self-directed Spring Ae
- 2016| International Women's day
- 2016 Leadman Annual Meeting
- 25/12/2015 | Merry Christmas +
- Creativity、 Modern and Effici
- State Food and Drug Administrat
- Thanksgiving | Leadman special
- The Week of Sincerity Construct
- Leadman Participated The 74th C
- Leadman Was one of The GEM List
- HAPPY LEADMAN| Enterprise Image
- Shen Guangqian---Leadman’s CH
- Leadman Marketing Team Particip
- Leadman Hold The First session
- 2015＂ Leadman first session o
- Runing, Bloomimg Leadman—2015
- The reserved restricted shares
- Resolution of the 25th Conferen
- Resolution of the 24th Conferen
- 2014 Annual Earnings Preannounc
- The legal opinion about adjusti
- Leadman Christmas Gourmet Festi
- Leadman Signs Significant Daily
- Leadman was cited for its excel
- Leadman was awarded the most be
- Resolution of the Fourth Extrao
- Additional legal opinions about
- Leadman’s Major Shareholder’
- 2014 Annual and 2015 Annual Mer
- Resolution of the 22nd Conferen
- Resolution of the 23rd Conferen
- The Independent Financial Consu
- The Management System of the Ra
- The General Risk Warning Notice
- The Financial Report and Audit
- The Notice of Fourth Extraordin
- The Independent Directors’ Op
- Leadman Held Investor Meeting
- Leadman attends the 72th CMEF-
- “Leadman” and“Enigma”es
- Leadman invites you to the 72th
- Leadman join hands with global
- Leadman’s new official websit
- Leadman with IDS team visiting
- Leadman awarded GEM Top 50 ente
- Leadman’s new product CI1000
- Medical Equipment Quality Journ
- Leadman holds 2014 Debate Conte
Company NewsThe current position： > en > News Center > Company News >
“Leadman” and“Enigma”establishing joint venture—expanding into molecular diagnostic market
作者：Leadman日期：2014-10-23
Molecular diagnostics has become an essential tool to individualized healthcare，with the development of various of technology.the global molecular diagnostics market which will be a sustainably developing market in future IVD market, is entering a period of rapid growth.
With purposes of entering market of molecular diagnostics rapidly,shortening the research period,perfecting business structure,riching product line, seizing the market opportunities,becoming one of the few diversified IVD companies who master fields of biochemical,immune.and molecular immunodiagnosis,Leadman is going to establish a joint venture with the British company,ENIGMA DIAGNOSTICS LIMITED ( Enigma).
Enigma is founed and registered at England and Wales in 2004.Enigma focusing in molecular diagnostic instruments,diagnostic products and other products, dedicating themselves in developing new products and commercializing programs,has mounts of products from own intellectual property and licensed intellectual property.
Leadman and Enigma is establishing a joint venture to cooperate in commercializing the Enjgma ML system,other diagnositic product lines,which will be tentatively named Engman Diagnostic(China)Co.,Ltd.Engman aspires to become a leading company of China mocular diagnostic-Poct market,and make Enigma ML system the supervisor standard of China molecular diagnostic-Poct market.
With purposes of entering market of molecular diagnostics rapidly,shortening the research period,perfecting business structure,riching product line, seizing the market opportunities,becoming one of the few diversified IVD companies who master fields of biochemical,immune.and molecular immunodiagnosis,Leadman is going to establish a joint venture with the British company,ENIGMA DIAGNOSTICS LIMITED ( Enigma).
Enigma is founed and registered at England and Wales in 2004.Enigma focusing in molecular diagnostic instruments,diagnostic products and other products, dedicating themselves in developing new products and commercializing programs,has mounts of products from own intellectual property and licensed intellectual property.
Leadman and Enigma is establishing a joint venture to cooperate in commercializing the Enjgma ML system,other diagnositic product lines,which will be tentatively named Engman Diagnostic(China)Co.,Ltd.Engman aspires to become a leading company of China mocular diagnostic-Poct market,and make Enigma ML system the supervisor standard of China molecular diagnostic-Poct market.
分享到：
